Sprint Bioscience recently sold its TREX1 program to Gilead. In an interview with BioStock, CEO Johan Emilsson explains the background to the deal, the strategic considerations that led to the transaction, and how the capital strengthens the company's ability to pursue its remaining programs. He also comments on the potential of the TREX1 project in immuno-oncology and what the deal means for the company's continued work.
See the interview biostock.se:
Sprint Bioscience: ”We have shown it is possible to make early deals”
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/